Proteomics International LaboratoriesLtd
Proteomics International Laboratories Ltd is an Australia-based medical technology company.
The business
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identifying up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.
Small Caps Research
No research on Proteomics International LaboratoriesLtd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise PIQ based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Proteomics International Gains ISO 15189 Certification for Precision Diagnostics Operations
Proteomics International (ASX: PIQ) has achieved a significant milestone with the granting of ISO 15189 certification for its Australian laboratory operations. The medical testing certification – which adds to Proteomics’ existing ISO 17025, ISO 13485 and CLIA certifications – will assist the company in commercialisation and clinical use of its suite of precision diagnostic tests, […]
Proteomics International Laboratories launches PromarkerD predictive test for diabetic kidney disease
Proteomics International Laboratories (ASX: PIQ) has officially launched its unique PromarkerD predictive test for diabetic kidney disease in Australia. PromarkerD is a clinically validated blood test that helps predict the risk of developing chronic diabetic kidney disease (DKD) in type 2 diabetes patients up to four years before clinical symptoms appear. Diabetes is the leading […]
Proteomics International Laboratories’ PromarkerD test paving the way for early detection of diabetic kidney disease
Proteomics International Laboratories (ASX: PIQ) has obtained what it describes as “groundbreaking” results in its development of treatments for deadly type 1 diabetes. More than 130,000 Australians live with type 1 diabetes, which currently accounts for around 10% of the nation’s diabetes cases and cannot be prevented. Globally, diabetes has emerged as the largest single […]
Proteomics International partners with University of Oxford to advance endometriosis study
Predictive diagnostics specialist Proteomics International Laboratories (ASX: PIQ) has signed an agreement with the University of Oxford to acquire approximately 600 patient plasma samples for a study into endometriosis. The samples will be used to further clinically validate the performance of the company’s PromarkerEndo diagnostic models for detecting the disease. Analysis is expected to be […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.